企業概要
Shattuck Labs, Inc. is a clinical-stage biotechnology entity dedicated to the development of therapeutic antibodies designed to treat inflammatory and immune-mediated diseases within the United States market. The company operates within the broader healthcare sector and the specific biotechnology industry, a landscape characterized by high capital requirements and significant regulatory hurdles prior to product commercialization. As of the latest available data, the company holds a market capitalization of 530.58 million dollars, generates annual revenue of 1.00 million dollars, and employs a workforce of 40 individuals. These valuation and operational figures indicate that the company is in a pre-revenue or early-stage commercialization phase, where the substantial market cap relative to current sales reflects investor expectations of potential future asset value derived from its pipeline rather than current earnings performance.
財務健全性
The company reported revenue of 1.00 million dollars over the trailing twelve months, while simultaneously posting a net income loss of 48,809,000 dollars and an EBITDA loss of 47,739,000 dollars. The substantial disparity between the minimal revenue of 1.00 million dollars and the net income loss of 48,809,000 dollars reveals a cost structure dominated by research and development expenditures, typical for clinical-stage entities, where operating costs significantly exceed current sales generation. Free cash flow stands at a negative 21,513,876 dollars, indicating that the company is currently consuming cash reserves to fund operations and clinical trials rather than generating positive cash flow from business activities. The gross margin is recorded at -195.1%, the operating margin at -5142.7%, and the profit margin at 0.0%; these negative or zero figures reflect the accounting treatment of development costs and the lack of profitable operations in the current stage of the business lifecycle. On the balance sheet, the company holds cash totaling 78.06 million dollars against total debt of 2.42 million dollars, with a debt-to-equity ratio of 2.94, suggesting a capital structure that relies heavily on equity financing while maintaining a net cash position despite the high debt-to-equity metric. The current ratio is 11.70, which indicates a robust short-term liquidity position where current assets significantly outweigh current liabilities, providing ample buffer to meet immediate obligations. Return on equity is -60.3% and return on assets is -35.3%, metrics that demonstrate the dilution of shareholder value and the consumption of asset base due to ongoing operational losses typical of early-stage biotechnology development.
バリュエーション評価
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, whereas the forward P/E is calculated at -14.70, implying that the market prices the stock based on anticipated future earnings rather than historical profitability. The price-to-book ratio is 5.39, indicating that the market values the company at more than five times its net asset book value, which often reflects the intangible value of the clinical pipeline and intellectual property not fully captured on the balance sheet. The price-to-sales ratio is 530.58 and the EV/EBITDA is -8.94; these alternative valuation metrics suggest that investors are pricing the company primarily on its revenue generation potential and market position rather than current profitability or cash flow generation capabilities. The 52-week high is 7.04 dollars and the 52-week low is 0.71 dollars, defining a trading range of approximately 900 percent, though the specific current trading price is not provided in the available data points. The beta value is 1.29, which signifies that the stock's price volatility is approximately 29 percent higher than the broader market benchmark, exposing investors to greater price fluctuations than large-cap securities.
Growth & Income
The revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, as the company has not yet established a consistent track record of positive earnings or stable revenue streams required to calculate these growth rates. Consequently, the company does not distribute dividends, resulting in a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically available for reinvestment, though currently consumed by negative earnings. Since the company is not a dividend payer, it follows the standard biotechnology model of reinvesting capital into research, development, and clinical trials to advance its pipeline of death receptor 3 blocking monoclonal antibodies. The overall growth and income profile is characterized by zero current income generation and reliance on external capital markets to fund the expansion of its therapeutic antibody portfolio for inflammatory and immune-mediated disease treatments.